JPS6360727B2 - - Google Patents
Info
- Publication number
- JPS6360727B2 JPS6360727B2 JP1995779A JP1995779A JPS6360727B2 JP S6360727 B2 JPS6360727 B2 JP S6360727B2 JP 1995779 A JP1995779 A JP 1995779A JP 1995779 A JP1995779 A JP 1995779A JP S6360727 B2 JPS6360727 B2 JP S6360727B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- erg
- cyanidin
- effect
- dark adaptation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- COAWNPJQKJEHPG-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 COAWNPJQKJEHPG-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 208000030533 eye disease Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 13
- 102000016912 Aldehyde Reductase Human genes 0.000 description 8
- 108010053754 Aldehyde reductase Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000004300 dark adaptation Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 6
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 5
- 206010007749 Cataract diabetic Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 201000007025 diabetic cataract Diseases 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 235000007336 cyanidin Nutrition 0.000 description 3
- -1 flavonoid compounds Chemical class 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000077233 Vaccinium uliginosum Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1995779A JPS55111418A (en) | 1979-02-21 | 1979-02-21 | Remedy for eye disease and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1995779A JPS55111418A (en) | 1979-02-21 | 1979-02-21 | Remedy for eye disease and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS55111418A JPS55111418A (en) | 1980-08-28 |
JPS6360727B2 true JPS6360727B2 (bg) | 1988-11-25 |
Family
ID=12013667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1995779A Granted JPS55111418A (en) | 1979-02-21 | 1979-02-21 | Remedy for eye disease and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS55111418A (bg) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8917323D0 (en) * | 1989-07-28 | 1989-09-13 | Inverni Della Beffa Spa | Methods and pharmaceutical compositions for the treatment of ophthalmic diseases |
JP2829451B2 (ja) | 1990-11-30 | 1998-11-25 | 大塚製薬株式会社 | 活性酸素抑制剤 |
GB9026792D0 (en) * | 1990-12-10 | 1991-01-30 | Idb Holding Spa | Process for synthesising anthocyanidins |
MY128323A (en) | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
US7772195B2 (en) * | 2004-07-29 | 2010-08-10 | Board Of Trustees Of Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
-
1979
- 1979-02-21 JP JP1995779A patent/JPS55111418A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS55111418A (en) | 1980-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8673979B2 (en) | Pharmaceutical compositions for headache, migraine, nausea and emesis | |
JP4642847B2 (ja) | シェーグレン症候群を含むドライアイ疾患治療用アデノシンa3レセプターアゴニスト | |
RU2460526C2 (ru) | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна | |
US4451477A (en) | Bendazac treatment of cataract | |
AU2001286178A1 (en) | Pharmaceutical compositions for headache, migraine, nausea and emesis | |
JPH11501282A (ja) | コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体 | |
LT3119B (en) | Pharmaceutical composition and process for the preparation thereof | |
JPS6360727B2 (bg) | ||
KR0149026B1 (ko) | 안구질환 치료용 조성물 | |
JP2811331B2 (ja) | 骨形成促進剤 | |
US4225607A (en) | Pharmaceutical composition containing a xanthine derivative | |
EP1362593B1 (en) | Cytidine-phosphocholine for the treatment of diabetic neuropathy | |
JP2710633B2 (ja) | 心臓疾患治療剤 | |
JP3024789B2 (ja) | 血圧降下剤 | |
US20090082455A1 (en) | Therapeutic agent for ophthalmic disease | |
JP3002700B2 (ja) | 抗エイズウイルス剤 | |
EP0342211B1 (en) | Treatment of arteriosclerosis by administration of l-tryptophan or l-5-hydroxytryptophan | |
JP2001500526A (ja) | 粘液溶解剤としての2−メチル−チアゾリジン−2,4−ジカルボン酸の使用 | |
TWI672145B (zh) | 預防及/或治療代謝疾病的醫藥組合物及其用途 | |
DE3642648A1 (de) | Verwendung von 6-allyl-2-amino-5,6,7,8-tetrahydro-4h-thiazolo-(5,4-d)azepin zur freisetzung von wachstumshormon | |
KR960014874B1 (ko) | 요산 배출용 조성물 | |
US4268518A (en) | Method of treating cystitis | |
JP3865450B2 (ja) | パーキンソニズム治療剤 | |
KR970001702B1 (ko) | 심장질환 치료용 조성물 | |
GB2150435A (en) | Pharmaceutical compositions |